Sarah Ketterer's BIIB Position Overview
Sarah Ketterer (via Causeway Capital Management LLC) currently holds 567.5K shares of Biogen Inc. (BIIB) worth $79.5 M, representing 1.05% of the portfolio. First purchased in 2016-Q2, this long-term strategic position has been held for 38 quarters.
Based on 13F filings, Sarah Ketterer has maintained a strategic position in BIIB, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 151.8K shares. Largest reduction occurred in Q4 2024, reducing 122.7K shares.
Analysis based on 13F filings available since 2013 Q2
Sarah Ketterer's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Sarah Ketterer
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2016 | +489,263 | New Buy | 489,263 | $276.33 |
| Q3 2016 | -84,819 | Reduce 17.34% | 404,444 | $351.61 |
| Q4 2016 | -404,444 | Sold Out | 404,444 | $0.00 |
| Q4 2024 | +281,702 | New Buy | 281,702 | $152.92 |
| Q1 2025 | +151,815 | Add 53.89% | 433,517 | $136.84 |
| Q2 2025 | +59,838 | Add 13.80% | 493,355 | $125.59 |
| Q3 2025 | +74,163 | Add 15.03% | 567,518 | $140.08 |
Sarah Ketterer's Biogen Investment FAQs
Sarah Ketterer first purchased Biogen Inc. (BIIB) in Q2 2016, acquiring 489,263 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer has held Biogen Inc. (BIIB) for 38 quarters since Q2 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer's largest addition to Biogen Inc. (BIIB) was in Q2 2016, adding 489,263 shares worth $135.2 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Sarah Ketterer's firm, Causeway Capital Management LLC, owns 567,518 shares of Biogen Inc. (BIIB), valued at approximately $79.5 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Biogen Inc. (BIIB) represents approximately 1.05% of Sarah Ketterer's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer's peak holding in Biogen Inc. (BIIB) was 567,518 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.